Resource Summary Report

Generated by FDI Lab - SciCrunch.org on Mar 31, 2025

Cleaved PARP (Asp214) (D64E10) XP Rabbit mAb

RRID:AB_10699459
Type: Antibody

Proper Citation

(Cell Signaling Technology Cat# 5625, RRID:AB_10699459)

Antibody Information

URL: http://antibodyregistry.org/AB_10699459

Proper Citation: (Cell Signaling Technology Cat# 5625, RRID:AB_10699459)

Target Antigen: Cleaved PARP (Asp214)

Host Organism: rabbit

Clonality: monoclonal

Comments: Applications: W, IP, IHC-P, IF-IC, F. Consolidation on 10/2018: AB_10699459, AB_10699460.

Antibody Name: Cleaved PARP (Asp214) (D64E10) XP Rabbit mAb

Description: This monoclonal targets Cleaved PARP (Asp214)

Target Organism: monkey, human

Clone ID: D64E10

Antibody ID: AB_10699459

Vendor: Cell Signaling Technology

Catalog Number: 5625

Record Creation Time: 20231110T070138+0000

Record Last Update: 20241115T050514+0000

Ratings and Alerts

No rating or validation information has been found for Cleaved PARP (Asp214) (D64E10) XP Rabbit mAb.

No alerts have been found for Cleaved PARP (Asp214) (D64E10) XP Rabbit mAb.

Data and Source Information

Source: Antibody Registry

Usage and Citation Metrics

We found 144 mentions in open access literature.

Listed below are recent publications. The full list is available at FDI Lab - SciCrunch.org.

Dunlap KN, et al. (2025) SLC7A5 is required for cancer cell growth under arginine-limited conditions. Cell reports, 44(1), 115130.

Bugide S, et al. (2024) ALK inhibitors suppress HCC and synergize with anti-PD-1 therapy and ABT-263 in preclinical models. iScience, 27(5), 109800.

Chen X, et al. (2024) Alarmin S100A8 imparts chemoresistance of esophageal cancer by reprogramming cancer-associated fibroblasts. Cell reports. Medicine, 5(6), 101576.

Oluwalana D, et al. (2024) Biological activity of a stable 6-aryl-2-benzoyl-pyridine colchicine-binding site inhibitor, 60c, in metastatic, triple-negative breast cancer. Cancer letters, 597, 217011.

Fukuda K, et al. (2024) Targeting WEE1 enhances the antitumor effect of KRAS-mutated non-small cell lung cancer harboring TP53 mutations. Cell reports. Medicine, 5(6), 101578.

Xi J, et al. (2024) Initiation of a ZAK?-dependent ribotoxic stress response by the innate immunity endoribonuclease RNase L. Cell reports, 43(4), 113998.

Liu C, et al. (2024) Plexin D1 emerges as a novel target in the development of neural lineage plasticity in treatment-resistant prostate cancer. Research square.

Mirzapoiazova T, et al. (2024) Teriflunomide/leflunomide synergize with chemotherapeutics by decreasing mitochondrial fragmentation via DRP1 in SCLC. iScience, 27(6), 110132.

Volegova MP, et al. (2024) The MYCN 5' UTR as a therapeutic target in neuroblastoma. Cell reports, 43(5), 114134.

Xiang S, et al. (2024) Identification of ATP-Competitive Human CMG Helicase Inhibitors for Cancer Intervention that Disrupt CMG-Replisome Function. Molecular cancer therapeutics,

23(11), 1568.

Tiburcio PDB, et al. (2024) Actinomycin D and bortezomib disrupt protein homeostasis in Wilms tumor. bioRxiv : the preprint server for biology.

Zhou C, et al. (2024) Anti-tumor efficacy of HRS-4642 and its potential combination with proteasome inhibition in KRAS G12D-mutant cancer. Cancer cell, 42(7), 1286.

Nag N, et al. (2024) Metallo-protease Peptidase M84 from Bacillusaltitudinis induces ROS-dependent apoptosis in ovarian cancer cells by targeting PAR-1. iScience, 27(6), 109828.

Debsharma S, et al. (2024) NSAID targets SIRT3 to trigger mitochondrial dysfunction and gastric cancer cell death. iScience, 27(4), 109384.

Chattopadhyay C, et al. (2024) Imipridones inhibit tumor growth and improve survival in an orthotopic liver metastasis mouse model of human uveal melanoma. bioRxiv : the preprint server for biology.

Yu PC, et al. (2024) SMARCA5 reprograms AKR1B1-mediated fructose metabolism to control leukemogenesis. Developmental cell, 59(15), 1954.

Huang P, et al. (2024) Peptostreptococcus stomatis promotes colonic tumorigenesis and receptor tyrosine kinase inhibitor resistance by activating ERBB2-MAPK. Cell host & microbe, 32(8), 1365.

Li X, et al. (2024) A small-molecule degrader selectively inhibits the growth of ALK-rearranged lung cancer with ceritinib resistance. iScience, 27(2), 109015.

Lim JS, et al. (2024) Energy?stress?mediated activation of AMPK sensitizes MPS1 kinase inhibition in triple?negative breast cancer. Oncology reports, 52(2).

Suh J, et al. (2024) Decoupling NAD+ metabolic dependency in chondrosarcoma by targeting the SIRT1-HIF-2? axis. Cell reports. Medicine, 5(1), 101342.